Gregory B. Sephton, Ph.D. is a Partner in the New York office of Haug Partners LLP. His litigation background covers diverse technologies involving lipid nanoparticles, medical devices, chemicals, pharmaceuticals and biologicals. Greg also advises cosmetics companies and obtained patent protection for their products.
He has extensive experience litigating billion dollar pharmaceutical and biotechnology patent cases, winning cases in federal district courts and at the Patent Trial and Appeal Board (PTAB). Greg also has in-depth experience under the Hatch-Waxman Act, litigating patents for antivirals hypnotics, anti-fungals, anti-bacterials, anti-ulcer drugs, along with various oral, intravenous and liposomal drug formulation technologies. He also has considerable involvement in intellectual property counseling, due diligence, and transactions. Gregory advises clients on trade secret protection, patent strategy, as well as on ex parte and inter partes patent re-examinations.
Gregory led Forward Pharma to a $1.25 billion settlement in its worldwide patent dispute with Biogen over rights to its Tecfidera® (multiple sclerosis) treatment.
Greg has a Ph.D. in biochemistry. Prior to joining Haug Partners LLP, Gregory was a Partner at Kramer Levin Naftalis & Frankel LLP and before that he was a partner at Fitzpatrick, Cella, Harper & Scinto (now Venable).